Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTA NASDAQ:NRXP NASDAQ:RCKT NASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$14.79+2.2%$13.57$4.96▼$17.15$427.61M1.01179,460 shs9,341 shsNRXPNRx Pharmaceuticals$3.02-0.8%$2.24$1.62▼$3.84$99.70M2.021.05 million shs366,210 shsRCKTRocket Pharmaceuticals$3.62+2.1%$4.11$2.19▼$7.39$394.47M0.522.99 million shs203,887 shsSNDLSNDL$1.47+2.4%$1.45$1.15▼$2.89$376.83M0.881.79 million shs1.21 million shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals+0.91%+5.62%+10.20%+7.42%+166.18%NRXPNRx Pharmaceuticals-1.62%+3.05%+38.18%+65.22%+49.75%RCKTRocket Pharmaceuticals-0.56%+3.21%-0.28%+6.31%-54.90%SNDLSNDL+1.42%-2.72%+5.15%-8.33%+5.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$14.79+2.2%$13.57$4.96▼$17.15$427.61M1.01179,460 shs9,341 shsNRXPNRx Pharmaceuticals$3.02-0.8%$2.24$1.62▼$3.84$99.70M2.021.05 million shs366,210 shsRCKTRocket Pharmaceuticals$3.62+2.1%$4.11$2.19▼$7.39$394.47M0.522.99 million shs203,887 shsSNDLSNDL$1.47+2.4%$1.45$1.15▼$2.89$376.83M0.881.79 million shs1.21 million shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals+0.91%+5.62%+10.20%+7.42%+166.18%NRXPNRx Pharmaceuticals-1.62%+3.05%+38.18%+65.22%+49.75%RCKTRocket Pharmaceuticals-0.56%+3.21%-0.28%+6.31%-54.90%SNDLSNDL+1.42%-2.72%+5.15%-8.33%+5.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.75Moderate Buy$20.2937.12% UpsideNRXPNRx Pharmaceuticals 2.50Moderate Buy$38.251,168.66% UpsideRCKTRocket Pharmaceuticals 2.39Hold$13.86283.32% UpsideSNDLSNDL 1.67Reduce$5.00241.30% UpsideCurrent Analyst Ratings BreakdownLatest NRXP, SNDL, ENTA, and RCKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.004/29/2026SNDLSNDL Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/27/2026NRXPNRx Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $49.004/27/2026NRXPNRx Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.004/24/2026RCKTRocket Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026ENTAEnanta Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.003/30/2026RCKTRocket Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $9.003/27/2026RCKTRocket Pharmaceuticals Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.003/26/2026ENTAEnanta Pharmaceuticals Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.003/24/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$65.32M6.57N/AN/A$3.03 per share4.88NRXPNRx Pharmaceuticals$1.23M81.39N/AN/A($0.54) per share-5.58RCKTRocket PharmaceuticalsN/AN/AN/AN/A$2.56 per shareN/ASNDLSNDL$677.32M0.56$0.12 per share12.61$3.08 per share0.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$81.89M-$3.20N/AN/AN/A-106.80%-78.58%-23.18%5/11/2026 (Estimated)NRXPNRx Pharmaceuticals-$28.62M-$1.39N/A2.45N/AN/AN/A-265.03%5/21/2026 (Estimated)RCKTRocket Pharmaceuticals-$223.12M-$2.01N/AN/AN/AN/A-64.74%-55.24%5/14/2026 (Estimated)SNDLSNDL-$11.29M-$0.03N/A36.63N/A-1.19%-1.02%-0.85%N/ALatest NRXP, SNDL, ENTA, and RCKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026NRXPNRx Pharmaceuticals-$0.01N/AN/AN/A$25.57 millionN/A5/14/2026Q1 2026RCKTRocket Pharmaceuticals-$0.41N/AN/AN/A$4.47 millionN/A5/11/2026Q2 2026ENTAEnanta Pharmaceuticals-$0.46N/AN/AN/A$17.03 millionN/A3/23/2026Q4 2025NRXPNRx Pharmaceuticals-$0.09$0.19+$0.28$0.19$7.53 million$0.98 million3/12/2026Q4 2025SNDLSNDL$0.01$0.0291+$0.0191$0.03$257.97 million$183.87 million2/26/2026Q4 2025RCKTRocket Pharmaceuticals-$0.42-$0.38+$0.04-$0.38N/AN/A2/9/2026Q1 2026ENTAEnanta Pharmaceuticals-$0.54-$0.42+$0.12-$0.42$16.14 million$18.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A4.444.44NRXPNRx PharmaceuticalsN/A0.310.31RCKTRocket Pharmaceuticals0.076.386.38SNDLSNDL0.124.843.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%NRXPNRx Pharmaceuticals4.27%RCKTRocket Pharmaceuticals98.39%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals11.48%NRXPNRx Pharmaceuticals6.40%RCKTRocket Pharmaceuticals21.30%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16029.02 million25.69 millionOptionableNRXPNRx Pharmaceuticals233.07 million30.95 millionOptionableRCKTRocket Pharmaceuticals240109.12 million85.88 millionOptionableSNDLSNDL2,751257.40 millionN/AOptionableNRXP, SNDL, ENTA, and RCKT HeadlinesRecent News About These CompaniesShould SNDL Stock Be in Your Portfolio Post Q1 Earnings?1 hour ago | zacks.comSNDL (NASDAQ:SNDL) Cut to Strong Sell at Zacks ResearchMay 2, 2026 | americanbankingnews.comSNDL Inc. (SNDL) Reports its First-quarter 2026 ResultsMay 1, 2026 | finance.yahoo.comSNDL Inc. (SNDL) Reports its First-quarter 2026 ResultsMay 1, 2026 | insidermonkey.comSNDL (NASDAQ:SNDL) Rating Lowered to "Strong Sell" at Zacks ResearchMay 1, 2026 | marketbeat.comSNDL Inc. Q1 2026 Earnings Call SummaryApril 30, 2026 | finance.yahoo.comSNDL Quarterly Revenue Dented By Soft Liquor, Cannabis Market ConditionsApril 30, 2026 | marketwatch.comSNDL sends pot stocks lower as market headwinds drive Q1 revenue missApril 30, 2026 | msn.comForget SNDL: HITI is a Significantly Better Cannabis StockApril 30, 2026 | 247wallst.comForget SNDL: HITI is a Significantly Better Cannabis StockApril 30, 2026 | 247wallst.comSNDL Inc. Disappoints With Declining Q1 2026 RevenueApril 30, 2026 | seekingalpha.comSNDL Inc. Earnings Call: Cost Cuts Amid Cannabis StrainApril 29, 2026 | tipranks.comSNDL Inc. (SNDL) Q1 2026 Earnings Call TranscriptApril 29, 2026 | seekingalpha.comSNDL Q1 Earnings Call HighlightsApril 29, 2026 | marketbeat.comSNDL (SNDL) Q1 2026 Earnings TranscriptApril 29, 2026 | fool.comSNDL Inc. Q1 2026 Earnings Call SummaryApril 29, 2026 | app.moby.coASNDL Reports First Quarter 2026 Financial and Operational ResultsApril 29, 2026 | finance.yahoo.comSNDL Reports First Quarter 2026 Financial and Operational ResultsApril 29, 2026 | globenewswire.comSNDL Inc. (NASDAQ:SNDL) Short Interest Up 39.5% in AprilApril 28, 2026 | marketbeat.comSNDL, Inc. Investigated by the Portnoy Law FirmApril 27, 2026 | globenewswire.com2 Top Marijuana Stocks For Investors Around The WorldApril 25, 2026 | marijuanastocks.comMNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGPU Prices Are Surging—3 Ways to Play the AI Chip ShortageBy Thomas Hughes | April 14, 2026The Market Is Selling Everything, but These 5 Stocks Aren't Breaking DownBy Bridget Bennett | April 10, 2026JBHT Burns Rubber, Hits the Highway to a $300 Price TagBy Thomas Hughes | April 17, 2026Microsoft Targets Trimmed: What It Means for InvestorsBy Chris Markoch | April 20, 2026Avis, CarMax, and Carvana: 3 Car Stocks Sharply DivergeBy Leo Miller | April 20, 2026NRXP, SNDL, ENTA, and RCKT Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$14.79 +0.31 (+2.17%) As of 10:52 AM Eastern This is a fair market value price provided by Massive. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.NRx Pharmaceuticals NASDAQ:NRXP$3.02 -0.03 (-0.82%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Rocket Pharmaceuticals NASDAQ:RCKT$3.62 +0.08 (+2.12%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.SNDL NASDAQ:SNDL$1.46 +0.04 (+2.45%) As of 10:53 AM Eastern This is a fair market value price provided by Massive. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
